Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial
Phase of Trial: Phase IV
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 02 Jul 2019 Planned End Date changed from 24 Nov 2023 to 23 Nov 2023.
- 02 Jul 2019 Planned primary completion date changed from 24 Nov 2023 to 23 Nov 2023.
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.